The colorectal cancer epidemic: challenges and opportunities for primary, secondary and tertiary prevention

Abstract

Colorectal cancer (CRC) is both one of the most common and one of the most preventable cancers globally, with powerful but strongly missed potential for primary, secondary and tertiary prevention. CRC incidence has traditionally been the highest in affluent Western countries, but it is now increasing rapidly with economic development in many other parts of the world. CRC shares several main risk factors, such as smoking, excessive alcohol consumption, physical inactivity and being overweight, with other common diseases; therefore, primary prevention efforts to reduce these risk factors are expected to have multiple beneficial effects that extend beyond CRC prevention, and should have high public health impact. A sizeable reduction in the incidence and mortality of CRC can also be achieved by offering effective screening tests, such as faecal immunochemical tests, flexible sigmoidoscopy and colonoscopy, in organised screening programmes which have been implemented in an increasing number of countries. Countries with early and high uptake rates of effective screening have exhibited major declines in CRC incidence and mortality, in contrast to most other countries. Finally, increasing evidence shows that the prognosis and quality of life of CRC patients can be substantially improved by tertiary prevention measures, such as the administration of low-dose aspirin and the promotion of physical activity.

References 103

1. 1.

   Ferlay J, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int. J. Cancer. 2015;136:E359-386.

   Not in our library10.1002/ijc.29210

2. 2.

   Babaei M, et al. Minimally invasive colorectal cancer surgery in Europe: implementation and outcomes. Med. (Baltim.). 2016;95:e3812.

   Not in our library10.1097/md.0000000000003812

3. 3.

   Brenner H, Kloor M, Pox CP. Colorectal cancer. Lancet. 2014;383:1490-1502.

   Not in our library10.1016/s0140-6736(13)61649-9

4. 4.

   Babaei M, et al. Neoadjuvant therapy in rectal cancer patients with clinical Stage II to III across European countries: variations and outcomes. Clin. Colorectal Cancer. 2018;17:e129-e142.

   Not in our library10.1016/j.clcc.2017.09.002

5. 5.

   Babaei M, et al. Administration of adjuvant chemotherapy for stage II-III colon cancer patients: an European population-based study. Int. J. Cancer. 2018;142:1480-1489.

   Not in our library10.1002/ijc.31168

6. 6.

   Jemal, A. et al. Annual report to the nation on the status of cancer, 1975–2014, featuring survival. J. Natl. Cancer Inst. 109 (2017).

   Not in our library10.1093/jnci/djx030

7. 7.

   Holleczek B, et al. On-going improvement and persistent differences in the survival for patients with colon and rectum cancer across Europe 1999–2007—Results from the EUROCARE-5 study. Eur. J. Cancer. 2015;51:2158-2168.

   Not in our library10.1016/j.ejca.2015.07.024

8. 8.

   Siegel RL, et al. Colorectal cancer statistics, 2017. CA Cancer J. Clin. 2017;67:177-193.

   Not in our library10.3322/caac.21395

9. 9.

   Arnold M, et al. Global patterns and trends in colorectal cancer incidence and mortality. Gut. 2017;66:683-691.

   Not in our library10.1136/gutjnl-2015-310912

10. 10.

    Brenner H, Schrotz-King P, Holleczek B, Katalinic A, Hoffmeister M. Declining bowel cancer incidence and mortality in Germany: an analysis of time trends in the first ten years after the introduction of screening colonoscopy. Dtsch. Ärzteblatt Int. 2016;113:101-106.

    Not in our library10.3238/arztebl.2016.0101

11. 11.

    Chen C, Lacke E, Stock C, Hoffmeister M, Brenner H. Colonoscopy and sigmoidoscopy use among older adults in different countries: a systematic review. Prev. Med. 2017;103:33-42.

    Not in our library10.1016/j.ypmed.2017.07.021

12. 12.

    Siegel, R. L. et al. Colorectal cancer incidence patterns in the United States, 1974–2013. J. Natl. Cancer Inst. 109 (2017).

    Not in our library10.1093/jnci/djw322

13. 13.

    Botteri E, et al. Smoking and colorectal cancer: a meta-analysis. JAMA. 2008;300:2765-2778.

    Not in our library10.1001/jama.2008.839

14. 14.

    Bagnardi V, et al. Alcohol consumption and site-specific cancer risk: a comprehensive dose-response meta-analysis. Br. J. Cancer. 2015;112:580-593.

    Not in our library10.1038/bjc.2014.579

15. 15.

    Freisling H, et al. Comparison of general obesity and measures of body fat distribution in older adults in relation to cancer risk: meta-analysis of individual participant data of seven prospective cohorts in Europe. Br. J. Cancer. 2017;116:1486-1497.

    Not in our library10.1038/bjc.2017.106

16. 16.

    Vieira AR, et al. Foods and beverages and colorectal cancer risk: a systematic review and meta-analysis of cohort studies, an update of the evidence of the WCRF-AICR continuous update project. Ann. Oncol. 2017;28:1788-1802.

    Not in our library10.1093/annonc/mdx171

17. 17.

    Boyle T, Keegel T, Bull F, Heyworth J, Fritschi L. Physical activity and risks of proximal and distal colon cancers: a systematic review and meta-analysis. J. Natl. Cancer Inst. 2012;104:1548-1561.

    Not in our library10.1093/jnci/djs354

18. 18.

    Algra AM, Rothwell PM. Effects of regular aspirin on long-term cancer incidence and metastasis: a systematic comparison of evidence from observational studies versus randomised trials. Lancet Oncol. 2012;13:518-527.

    Not in our library10.1016/s1470-2045(12)70112-2

19. 19.

    Cao Y, et al. Population-wide impact of long-term use of aspirin and the risk for cancer. JAMA Oncol. 2016;2:762-769.

    Not in our library10.1001/jamaoncol.2015.6396

20. 20.

    Green J, et al. Menopausal hormone therapy and risk of gastrointestinal cancer: nested case-control study within a prospective cohort, and meta-analysis. Int. J. Cancer. 2012;130:2387-2396.

    Not in our library10.1002/ijc.26236

21. 21.

    http://www.tobaccoatlas.org/topic/cigarette-use-globally/ Accessed 3 Jan 2018.

    Not in our library

22. 22.
    Worldwide trends in body-mass index, underweight, overweight, and obesity from 1975 to 2016: a pooled analysis of 2416 population-based measurement studies in 128·9 million children, adolescents, and adults · 2017

    No notice
23. 23.

    Young JP, et al. Rising incidence of early-onset colorectal cancer in Australia over two decades: report and review. J. Gastroenterol. Hepatol. 2015;30:6-13.

    Not in our library10.1111/jgh.12792

24. 24.

    Hidayat K, Yang CM, Shi BM. Body fatness at an early age and risk of colorectal cancer. Int. J. Cancer. 2018;142:729-740.

    Not in our library10.1002/ijc.31100

25. 25.

    Ogino S, Chan AT, Fuchs CS, Giovannucci E. Molecular pathological epidemiology of colorectal neoplasia: an emerging transdisciplinary and interdisciplinary field. Gut. 2011;60:397-411.

    Not in our library10.1136/gut.2010.217182

26. 26.

    Hughes LAE, Simons CCJM, van den Brandt PA, van Engeland M, Weijenberg MP. Lifestyle, diet, and colorectal cancer risk according to (Epi)genetic instability: current evidence and future directions of molecular pathological epidemiology. Curr. Colorectal Cancer Rep. 2017;13:455-469.

    Not in our library10.1007/s11888-017-0395-0

27. 27.

    Rescigno, T., Micolucci, L., Tecce, M. F., Capasso, A. Bioactive nutrients and nutrigenomics in age-related diseases. Molecules22, pii: E105 (2017).

    Not in our library10.3390/molecules22010105

28. 28.

    Slattery ML, et al. Infrequently expressed miRNAs in colorectal cancer tissue and tumor molecular phenotype. Mod. Pathol. 2017;30:1152-1169.

    Not in our library10.1038/modpathol.2017.38

29. 29.

    Ogino S, et al. Integrative analysis of exogenous, endogenous, tumour and immune factors for precision medicine. Gut. 2018;67:1168-1180.

    Not in our library10.1136/gutjnl-2017-315537

30. 30.

    Carr PR, et al. Lifestyle factors and risk of sporadic colorectal cancer by microsatellite instability status: a systematic review and meta-analyses. Ann. Oncol. 2018;29:825-834.

    Not in our library10.1093/annonc/mdy059

31. 31.

    Oosterhoff M, Joore M, Ferreira I. The effects of school-based lifestyle interventions on body mass index and blood pressure: a multivariate multilevel meta-analysis of randomized controlled trials. Obes. Rev. 2016;17:1131-1153.

    Not in our library10.1111/obr.12446

32. 32.

    Bibbins-Domingo K. Aspirin use for the primary prevention of cardiovascular disease and colorectal cancer: U.S. preventive services task force recommendation statement. Ann. Intern. Med. 2016;164:836-845.

    Not in our library10.7326/m16-0577

33. 33.

    Singh Ranger G. The role of aspirin in colorectal cancer chemoprevention. Crit. Rev. Oncol. Hematol. 2016;104:87-90.

    Not in our library10.1016/j.critrevonc.2016.05.011

34. 34.

    Marjoribanks J, Farquhar C, Roberts H, Lethaby A, Lee J. Long-term hormone therapy for perimenopausal and postmenopausal women. Cochrane Database Syst. Rev. 2017;1:Cd004143.

    Not in our library10.1002/14651858.cd004143.pub5

35. 35.

    Gartlehner G, et al. Hormone therapy for the primary prevention of chronic conditions in postmenopausal women: evidence report and systematic review for the US Preventive Services Task Force. JAMA. 2017;318:2234-2249.

    Not in our library10.1001/jama.2017.16952

36. 36.

    Brenner H, Altenhofen L, Stock C, Hoffmeister M. Natural history of colorectal adenomas: birth cohort analysis among 3.6 million participants of screening colonoscopy. Cancer Epidemiol. Biomark. Prev. 2013;22:1043-1051.

    Not in our library10.1158/1055-9965.epi-13-0162

37. 37.

    Hewitson P, Glasziou P, Watson E, Towler B, Irwig L. Cochrane systematic review of colorectal cancer screening using the fecal occult blood test (hemoccult): an update. Am. J. Gastroenterol. 2008;103:1541-1549.

    Not in our library10.1111/j.1572-0241.2008.01875.x

38. 38.

    Scholefield JH, Moss SM, Mangham CM, Whynes DK, Hardcastle JD. Nottingham trial of faecal occult blood testing for colorectal cancer: a 20-year follow-up. Gut. 2012;61:1036-1040.

    Not in our library10.1136/gutjnl-2011-300774

39. 39.

    Shaukat A, et al. Long-term mortality after screening for colorectal cancer. N. Engl. J. Med. 2013;369:1106-1114.

    Not in our library10.1056/nejmoa1300720

40. 40.

    Hol L, et al. Screening for colorectal cancer: randomised trial comparing guaiac-based and immunochemical faecal occult blood testing and flexible sigmoidoscopy. Gut. 2010;59:62-68.

    Not in our library10.1136/gut.2009.177089

41. 41.

    Brenner H, Tao S. Superior diagnostic performance of faecal immunochemical tests for haemoglobin in a head-to-head comparison with guaiac based faecal occult blood test among 2235 participants of screening colonoscopy. Eur. J. Cancer. 2013;49:3049-3054.

    Not in our library10.1016/j.ejca.2013.04.023

42. 42.

    Robertson DJ, et al. Recommendations on fecal immunochemical testing to screen for colorectal neoplasia: a consensus statement by the US Multi-Society Task Force on colorectal cancer. Am. J. Gastroenterol. 2017;112:37-53.

    Not in our library10.1038/ajg.2016.492

43. 43.

    Gies Anton, Bhardwaj Megha, Stock Christian, Schrotz-King Petra, Brenner Hermann. Quantitative fecal immunochemical tests for colorectal cancer screening. International Journal of Cancer. 2018;143(2):234-244.

    Not in our library10.1002/ijc.31233

44. 44.

    Rex DK, et al. Colorectal cancer screening: recommendations for physicians and patients from the U.S. Multi-Society Task Force on colorectal cancer. Gastroenterology. 2017;153:307-323.

    Not in our library10.1053/j.gastro.2017.05.013

45. 45.

    Schreuders EH, et al. Colorectal cancer screening: a global overview of existing programmes. Gut. 2015;64:1637-1649.

    Not in our library10.1136/gutjnl-2014-309086

46. 46.

    van der Vlugt M, et al. Adherence to colorectal cancer screening: four rounds of faecal immunochemical test-based screening. Br. J. Cancer. 2017;116:44-49.

    Not in our library10.1038/bjc.2016.399

47. 47.

    Imperiale TF, et al. Multitarget stool DNA testing for colorectal-cancer screening. N. Engl. J. Med. 2014;370:1287-1297.

    Not in our library10.1056/nejmoa1311194

48. 48.

    Brenner H, Werner S, Chen H. Multitarget stool DNA testing for colorectal-cancer screening. N. Engl. J. Med. 2014;371:184-185.

    Not in our library10.1056/nejmc1405215

49. 49.

    Brenner H, Chen H. Fecal occult blood versus DNA testing: indirect comparison in a colorectal cancer screening population. Clin. Epidemiol. 2017;9:377-384.

    Not in our library10.2147/clep.s136565

50. 50.

    Lin JS, et al. Screening for colorectal cancer: updated evidence report and systematic review for the US Preventive Services Task Force. JAMA. 2016;315:2576-2594.

    Not in our library10.1001/jama.2016.3332

51. 51.
    Long term effects of once-only flexible sigmoidoscopy screening after 17 years of follow-up: the UK Flexible Sigmoidoscopy Screening randomised controlled trial · 2017

    No notice
52. 52.

    Segnan N, et al. Once-only sigmoidoscopy in colorectal cancer screening: follow-up findings of the Italian Randomized Controlled Trial—SCORE. J. Natl. Cancer Inst. 2011;103:1310-1322.

    Not in our library10.1093/jnci/djr284

53. 53.

    Holme O, et al. Effect of flexible sigmoidoscopy screening on colorectal cancer incidence and mortality: a randomized clinical trial. JAMA. 2014;312:606-615.

    Not in our library10.1001/jama.2014.8266

54. 54.

    Schoen RE, et al. Colorectal-cancer incidence and mortality with screening flexible sigmoidoscopy. N. Engl. J. Med. 2012;366:2345-2357.

    Not in our library10.1056/nejmoa1114635

55. 55.

    Brenner H, Stock C, Hoffmeister M. Effect of screening sigmoidoscopy and screening colonoscopy on colorectal cancer incidence and mortality: systematic review and meta-analysis of randomised controlled trials and observational studies. BMJ. 2014;348:g2467.

    Not in our library10.1136/bmj.g2467

56. 56.

    Kaminski MF, et al. The NordICC Study: rationale and design of a randomized trial on colonoscopy screening for colorectal cancer. Endoscopy. 2012;44:695-702.

    Not in our library10.1055/s-0032-1306895

57. 57.

    Doubeni CA, et al. Effectiveness of screening colonoscopy in reducing the risk of death from right and left colon cancer: a large community-based study. Gut. 2018;67:291-298.

    Not in our library10.1136/gutjnl-2016-312712

58. 58.

    Brenner H, Stock C, Hoffmeister M. In the era of widespread endoscopy use, randomized trials may strongly underestimate the effects of colorectal cancer screening. J. Clin. Epidemiol. 2013;66:1144-1150.

    Not in our library10.1016/j.jclinepi.2013.05.008

59. 59.

    Chen C, Stock C, Hoffmeister M, Brenner H. Public health impact of colonoscopy use on colorectal cancer mortality in Germany and the United States. Gastrointest. Endosc. 2018;87:213-221.e212.

    Not in our library10.1016/j.gie.2017.04.005

60. 60.

    Wolf AMD, et al. Colorectal cancer screening for average-risk adults: 2018 guideline update from the American Cancer Society. CA Cancer J. Clin. 2018;68:250-281.

    Not in our library10.3322/caac.21457

61. 61.

    Frampton MJ, et al. Implications of polygenic risk for personalised colorectal cancer screening. Ann. Oncol. 2016;27:429-434.

    Not in our library10.1093/annonc/mdv540

62. 62.

    Weigl K, et al. Strongly enhanced colorectal cancer risk stratification by combining family history and genetic risk score. Clin. Epidemiol. 2018;10:143-152.

    Not in our library10.2147/clep.s145636

63. 63.

    Jeon J, et al. Determining risk of colorectal cancer and starting age of screening based on lifestyle, environmental, and genetic factors. Gastroenterology. 2018;154:2152-2164.e19.

    Not in our library10.1053/j.gastro.2018.02.021

64. 64.

    Weigl K, et al. Genetic risk score is associated with prevalence of advanced neoplasms in a colorectal cancer screening population. Gastroenterology. 2018;155:88-98.e10.

    Not in our library10.1053/j.gastro.2018.03.030

65. 65.

    Lansdorp-Vogelaar I, Knudsen AB, Brenner H. Cost-effectiveness of colorectal cancer screening. Epidemiol. Rev. 2011;33:88-100.

    Not in our library10.1093/epirev/mxr004

66. 66.

    van Hees F, et al. The value of models in informing resource allocation in colorectal cancer screening: the case of The Netherlands. Gut. 2015;64:1985-1997.

    Not in our library10.1136/gutjnl-2015-309316

67. 67.

    Brenner H, Altenhofen L, Stock C, Hoffmeister M. Prevention, early detection, and overdiagnosis of colorectal cancer within 10 years of screening colonoscopy in Germany. Clin. Gastroenterol. Hepatol. 2015;13:717-723.

    Not in our library10.1016/j.cgh.2014.08.036

68. 68.

    Knudsen AB, et al. Estimation of benefits, burden, and harms of colorectal cancer screening strategies: modeling study for the US Preventive Services Task Force. JAMA. 2016;315:2595-2609.

    Not in our library10.1001/jama.2016.6828

69. 69.

    Lew JB, et al. Long-term evaluation of benefits, harms, and cost-effectiveness of the National Bowel Cancer Screening Program in Australia: a modelling study. Lancet Public Health. 2017;2:e331-e340.

    Not in our library10.1016/s2468-2667(17)30105-6

70. 70.

    Walter V, Jansen L, Hoffmeister M, Brenner H. Smoking and survival of colorectal cancer patients: systematic review and meta-analysis. Ann. Oncol. 2014;25:1517-1525.

    Not in our library10.1093/annonc/mdu040

71. 71.

    Walter V, et al. Smoking and survival of colorectal cancer patients: population-based study from Germany. Int. J. Cancer. 2015;137:1433-1445.

    Not in our library10.1002/ijc.29511

72. 72.

    Ordonez-Mena JM, et al. Impact of prediagnostic smoking and smoking cessation on colorectal cancer prognosis: a meta-analysis of individual patient data from cohorts within the CHANCES consortium. Ann. Oncol. 2018;29:472-483.

    Not in our library10.1093/annonc/mdx761

73. 73.

    Walter V, et al. Alcohol consumption and survival of colorectal cancer patients: a population-based study from Germany. Am. J. Clin. Nutr. 2016;103:1497-1506.

    Not in our library10.3945/ajcn.115.127092

74. 74.

    Sharma A, et al. Tobacco smoking and postoperative outcomes after colorectal surgery. Ann. Surg. 2013;258:296-300.

    Not in our library10.1097/sla.0b013e3182708cc5

75. 75.

    Dinicola S, et al. Nicotine increases survival in human colon cancer cells treated with chemotherapeutic drugs. Toxicol. Vitr. 2013;27:2256-2263.

    Not in our library10.1016/j.tiv.2013.09.020

76. 76.

    Warren GW, et al. Nicotinic modulation of therapeutic response in vitro and in vivo. Int. J. Cancer. 2012;131:2519-2527.

    Not in our library10.1002/ijc.27556

77. 77.

    Vincenzi B, et al. Cigarettes smoking habit may reduce benefit from cetuximab-based treatment in advanced colorectal cancer patients. Expert. Opin. Biol. Ther. 2009;9:945-949.

    Not in our library10.1517/14712590903081694

78. 78.

    Cucina A, et al. Nicotine stimulates proliferation and inhibits apoptosis in colon cancer cell lines through activation of survival pathways. J. Surg. Res. 2012;178:233-241.

    Not in our library10.1016/j.jss.2011.12.029

79. 79.

    Wei PL, et al. Nicotine enhances colon cancer cell migration by induction of fibronectin. Ann. Surg. Oncol. 2011;18:1782-1790.

    Not in our library10.1245/s10434-010-1504-3

80. 80.

    Van Blarigan EL, Meyerhardt JA. Role of physical activity and diet after colorectal cancer diagnosis. J. Clin. Oncol. 2015;33:1825-1834.

    Not in our library10.1200/jco.2014.59.7799

81. 81.

    Otto SJ, et al. Association of change in physical activity and body weight with quality of life and mortality in colorectal cancer: a systematic review and meta-analysis. Support. Care Cancer. 2015;23:1237-1250.

    Not in our library10.1007/s00520-014-2480-0

82. 82.

    Walter V, et al. Physical activity and survival of colorectal cancer patients: Population-based study from Germany. Int. J. Cancer. 2017;140:1985-1997.

    Not in our library10.1002/ijc.30619

83. 83.

    Friedenreich CM, Shaw E, Neilson HK, Brenner DR. Epidemiology and biology of physical activity and cancer recurrence. J. Mol. Med. 2017;95:1029-1041.

    Not in our library10.1007/s00109-017-1558-9

84. 84.

    Lee J, Meyerhardt JA, Giovannucci E, Jeon JY. Association between body mass index and prognosis of colorectal cancer: a meta-analysis of prospective cohort studies. PLoS One. 2015;10:e0120706.

    Not in our library10.1371/journal.pone.0120706

85. 85.

    Walter V, et al. Prognostic relevance of prediagnostic weight loss and overweight at diagnosis in patients with colorectal cancer. Am. J. Clin. Nutr. 2016;104:1110-1120.

    Not in our library10.3945/ajcn.116.136531

86. 86.

    Carr PR, et al. Associations of red and processed meat with survival after colorectal cancer and differences according to timing of dietary assessment. Am. J. Clin. Nutr. 2016;103:192-200.

    Not in our library10.3945/ajcn.115.121145

87. 87.

    van Zutphen M, Kampman E, Giovannucci EL, van Duijnhoven FJB. Lifestyle after colorectal cancer diagnosis in relation to survival and recurrence: a review of the literature. Curr. Colorectal Cancer Rep. 2017;13:370-401.

    Not in our library10.1007/s11888-017-0386-1

88. 88.

    Van Blarigan EL, et al. Association of survival with adherence to the American Cancer Society Nutrition and Physical Activity Guidelines for Cancer Survivors after colon cancer diagnosis: the CALGB 89803/Alliance trial. JAMA Oncol. 2018;4:783-790.

    Not in our library10.1001/jamaoncol.2018.0126

89. 89.

    Li P, et al. Aspirin use after diagnosis but not prediagnosis improves established colorectal cancer survival: a meta-analysis. Gut. 2015;64:1419-1425.

    Not in our library10.1136/gutjnl-2014-308260

90. 90.

    Sostres C, Gargallo CJ, Lanas A. Aspirin, cyclooxygenase inhibition and colorectal cancer. World J. Gastrointest. Pharmacol. Ther. 2014;5:40-49.

    Not in our library10.4292/wjgpt.v5.i1.40

91. 91.

    Frouws MA, et al. The mortality reducing effect of aspirin in colorectal cancer patients: Interpreting the evidence. Cancer Treat. Rev. 2017;55:120-127.

    Not in our library10.1016/j.ctrv.2016.12.008

92. 92.
    Metformin as an adjuvant treatment for cancer: a systematic review and meta-analysis · 2016

    No notice
93. 93.

    Weberpals J, Jansen L, Carr PR, Hoffmeister M, Brenner H. Beta blockers and cancer prognosis—The role of immortal time bias: a systematic review and meta-analysis. Cancer Treat. Rev. 2016;47:1-11.

    Not in our library10.1016/j.ctrv.2016.04.004

94. 94.

    Garland CF, Gorham ED. Dose-response of serum 25-hydroxyvitamin D in association with risk of colorectal cancer: a meta-analysis. J. Steroid Biochem. Mol. Biol. 2017;168:1-8.

    Not in our library10.1016/j.jsbmb.2016.12.003

95. 95.

    Zgaga L, et al. Plasma vitamin D concentration influences survival outcome after a diagnosis of colorectal cancer. J. Clin. Oncol. 2014;32:2430-2439.

    Not in our library10.1200/jco.2013.54.5947

96. 96.

    Maalmi H, et al. Relationship of very low serum 25-hydroxyvitamin D3 levels with long-term survival in a large cohort of colorectal cancer patients from Germany. Eur. J. Epidemiol. 2017;32:961-971.

    Not in our library10.1007/s10654-017-0298-z

97. 97.

    Ng K, et al. SUNSHINE: Randomized double-blind phase II trial of vitamin D supplementation in patients with previously untreated metastatic colorectal cancer. J. Clin. Oncol. 2017;35(15_suppl):3506.

    Not in our library10.1200/jco.2017.35.15_suppl.3506

98. 98.

    Brenner H, Jansen L, Saum KU, Holleczek B, Schöttker B. Vitamin D supplementation trials aimed at reducing mortality have much higher power when focusing on people with low serum 25-hydroxyvitamin D concentrations. J. Nutr. 2017;147:1325-1333.

    Not in our library10.3945/jn.117.250191

99. 99.

    World Cancer Research Fund, American Institute for Cancer Research. Continuous Update Project analysing research on cancer prevention and survival. Diet, nutrition, physical activity and colorectal cancer 2017. https://www.wcrf.org/sites/default/files/Colorectal-Cancer-2017-Report.pdf. Accessed 16 Mar 2018.

    Not in our library

100. 100.

     The German Centre for Cancer Registry Data (ZfKD). https://www.krebsdaten.de/Krebs/EN/Database/databasequery_step1_node.html. Accessed 3 Feb 2018.

     Not in our library

101. 101.

     U.S. Cancer Statistics Working Group. United States Cancer Statistics: 1999–2014 Incidence and Mortality Web-based Report. Atlanta: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention and National Cancer Institute; 2017. https://nccd.cdc.gov/uscs/. Accessed 3 Feb 2018.

     Not in our library

102. 102.

     The Netherlands Comprehensive Cancer Organisation (IKNL). The Netherlands Cancer Registry. https://www.cijfersoverkanker.nl/home-36.html. Accessed 3 Feb 2018.

     Not in our library

103. 103.

     Office for National Statistics (ONS). Cancer Registration Statistics, England. https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/datasets/cancerregistrationstatisticscancerregistrationstatisticsengland. Accessed 3 Feb 2018.

     Not in our library

Cited by papers we hold 1

• E2F1 promotes cell cycle progression by stabilizing spindle fiber in colorectal cancer cells · 2022
  Not checked

Reads

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.